IL-34 antibody (Biotin)

Catalog No. ABIN2660792

Product Details anti-IL-34 Antibody (Biotin)

Target: IL-34 (IL34) (Interleukin 34 (IL34))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL-34 antibody is conjugated to Biotin

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Clone: E033B8

Isotype: IgG2a lambda

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for IL-34

Target: IL-34 (IL34) (Interleukin 34 (IL34))

Alternative Name: IL-34 (IL34 Products)

Synonyms: C16orf77 antibody, IL-34 antibody, 2010004A03Rik antibody, AI593503 antibody, C18H16ORF77 antibody, interleukin 34 antibody, IL34 antibody, Il34 antibody

Background: Human IL-34 shares a sequence identity of 99.6 % , 72 % and 71 % with chimpanzee, rat, and mouse IL-34, respectively, on the amino acid level. The IL-34 gene is syntenic in the human, chimpanzee, rat, and mouse genomes. IL-34 has no apparent consensus structural domain or motif, and does not share sequence homology with M-CSF, nevertheless, it binds to the CSFR. These two cytokines are not identical in biological activity and signal activation. IL-34 and CSF show an equivalent ability to support cell growth or survival. However, these cytokines are differing in their ability to induce the production of chemokines (MCP-1 and eotaxin-2) in primary macrophages, the morphological change in TF-1-fms cells, and the migration of J774A.1 cells. The use of monoclonal antibodies against the CSFR suggests differential domain binding of the receptor to IL-34 and CSF and as a result, different bioactivities and signal activation kinetics/strength are produced for these cytokines.

Pathways: RTK Signaling